Now Live The BioInsights Podcast Modernizing cell therapy manufacturing to reduce vein-to-vein times

Listen now

GPB Scientific becomes Curate Biosciences, targets 50% reduction in autologous cell therapy costs

GPB Scientific is now known as Curate Biosciences, a name it says reflects more the work it is doing for cell and gene therapy providers.

The company has spent six years working on a platform focused on cell potency and recovery; it says it has cracked one of the biggest problems in cell therapy; extracting enough potent cells to treat chronically sick patients.

Read the full story.